CY1124288T1 - Cmv εμβολια - Google Patents
Cmv εμβολιαInfo
- Publication number
- CY1124288T1 CY1124288T1 CY20211100578T CY211100578T CY1124288T1 CY 1124288 T1 CY1124288 T1 CY 1124288T1 CY 20211100578 T CY20211100578 T CY 20211100578T CY 211100578 T CY211100578 T CY 211100578T CY 1124288 T1 CY1124288 T1 CY 1124288T1
- Authority
- CY
- Cyprus
- Prior art keywords
- reactivation
- cytomegalovirus infections
- cmv vaccine
- vaccines
- methods
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 206010011831 Cytomegalovirus infection Diseases 0.000 abstract 3
- 230000007420 reactivation Effects 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10041—Use of virus, viral particle or viral elements as a vector
- C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361911135P | 2013-12-03 | 2013-12-03 | |
| US201462055699P | 2014-09-26 | 2014-09-26 | |
| PCT/EP2014/076466 WO2015082570A1 (en) | 2013-12-03 | 2014-12-03 | Cmv vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124288T1 true CY1124288T1 (el) | 2022-07-22 |
Family
ID=52232138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100578T CY1124288T1 (el) | 2013-12-03 | 2021-06-29 | Cmv εμβολια |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10111945B2 (enExample) |
| EP (2) | EP3077519B1 (enExample) |
| JP (2) | JP6818551B2 (enExample) |
| CN (2) | CN105980570B (enExample) |
| AU (2) | AU2014359276B2 (enExample) |
| CA (1) | CA2932318C (enExample) |
| CY (1) | CY1124288T1 (enExample) |
| DK (1) | DK3077519T3 (enExample) |
| ES (1) | ES2868427T3 (enExample) |
| HR (1) | HRP20211015T1 (enExample) |
| HU (1) | HUE054579T2 (enExample) |
| LT (1) | LT3077519T (enExample) |
| PL (1) | PL3077519T3 (enExample) |
| PT (1) | PT3077519T (enExample) |
| RS (1) | RS61993B1 (enExample) |
| SI (1) | SI3077519T1 (enExample) |
| WO (1) | WO2015082570A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2604695B1 (en) | 2007-12-27 | 2022-11-16 | Universität Zürich | Replication-defective arenavirus vectors |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| AU2014359276B2 (en) | 2013-12-03 | 2021-01-28 | Hookipa Biotech Gmbh | CMV vaccines |
| PL3218504T3 (pl) | 2014-11-13 | 2021-02-08 | Université De Genève | Trójsegmentowe arenawirusy jako wektory szczepionkowe |
| EP3031822A1 (en) * | 2014-12-08 | 2016-06-15 | Novartis AG | Cytomegalovirus antigens |
| WO2016198531A2 (en) | 2015-06-10 | 2016-12-15 | Hookipa Biotech Ag | Hpv vaccines |
| CA3002922A1 (en) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| CN108779472B (zh) | 2015-11-04 | 2022-09-09 | 霍欧奇帕生物科技有限公司 | 针对乙型肝炎病毒的疫苗 |
| US11266727B2 (en) | 2015-11-12 | 2022-03-08 | Hookipa Biotech Gmbh | Arenavirus particles as cancer vaccines |
| US11260090B2 (en) | 2016-03-08 | 2022-03-01 | University Of Vermont And State Agricultural College | Modified arenavirus |
| IL262207B1 (en) | 2016-04-15 | 2025-09-01 | Univ Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| EP3528821A4 (en) * | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | HUMAN CYTOMEGALOVIRUS VACCINE |
| US20200206334A1 (en) | 2016-11-04 | 2020-07-02 | Hookipa Biotech Gmbh | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
| IL269892B2 (en) | 2017-04-14 | 2024-04-01 | Regenxbio Inc | Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2 sulfatase (ids) produced by human neural or glial cells |
| WO2018204080A1 (en) * | 2017-05-02 | 2018-11-08 | The Scripps Research Institute | Compositions and methods related to arenavirus immunogens |
| WO2019216929A1 (en) * | 2018-05-11 | 2019-11-14 | City Of Hope | Mva vectors for expressing multiple cytomegalovirus (cmv) antigens and use thereof |
| MX2021004273A (es) | 2018-10-17 | 2021-12-10 | Glaxosmithkline Biologicals Sa | Proteinas de citomegalovirus modificadas y complejos estabilizados. |
| CN113164585B (zh) * | 2018-12-10 | 2023-08-29 | Km生物医薬股份公司 | 用于预防或治疗巨细胞病毒的先天性感染的疫苗 |
| CN114981443A (zh) * | 2019-11-07 | 2022-08-30 | 巴塞尔大学 | 作为载体的沙粒病毒 |
| US20230248821A1 (en) * | 2020-06-09 | 2023-08-10 | Km Biologics Co., Ltd. | Fusion Protein of Pentamer and GB of Cytomegalovirus, and Vaccine Containing Said Fusion Protein |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| RU2756557C1 (ru) * | 2020-11-02 | 2021-10-01 | Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") | Способ опосредованного определения титра вируса ящура в неинактивированном сырье для вакцины при амплификации вирусной нуклеиновой кислоты и детекции РНК-ампликонов с применением технологии молекулярных биконов |
| KR20230145386A (ko) | 2021-02-10 | 2023-10-17 | 리젠엑스바이오 인크. | 재조합 인간 이두로네이트-2-설파타아제(ids)를 사용한 점액다당류증 ii의 치료 |
| US20240229073A1 (en) | 2021-05-13 | 2024-07-11 | Hookipa Biotech Gmbh | Arenaviruses as vectors |
| WO2024163912A2 (en) * | 2023-02-03 | 2024-08-08 | The Children's Medical Center Corporation | Vaccine and therapeutic protein delivery compositions comprising fusion proteins |
| WO2025056782A1 (en) | 2023-09-15 | 2025-03-20 | Hookipa Biotech Gmbh | Arenavirus formulations, methods and uses thereof |
| CN118221773B (zh) * | 2024-02-05 | 2025-09-09 | 首都医科大学附属北京儿童医院保定医院 | 与HLA相关的CMV pp65表位疫苗组合物与应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| JP2607712B2 (ja) * | 1988-01-29 | 1997-05-07 | カイロン コーポレイション | 組換えｃｍｖ中和タンパク |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| EP1265916B1 (en) * | 2000-03-21 | 2005-12-21 | Genzyme Corporation | Therapeutic anti-cytomegalovirus compounds |
| DE102004034461B4 (de) * | 2004-07-16 | 2008-02-07 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren |
| AU2006302794B2 (en) * | 2005-02-15 | 2011-08-04 | Children's Hospital, Inc. | New live virus vaccines |
| CA2646891A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| ES2376492T3 (es) | 2006-03-23 | 2012-03-14 | Novartis Ag | Compuestos de imidazoquinoxalina como inmunomoduladores. |
| EP2604695B1 (en) | 2007-12-27 | 2022-11-16 | Universität Zürich | Replication-defective arenavirus vectors |
| US8580276B2 (en) * | 2009-06-05 | 2013-11-12 | City Of Hope | Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof |
| JP2012530500A (ja) * | 2009-06-26 | 2012-12-06 | ヴェクトライト バイオメディカ インコーポレイテッド | サイトメガロウイルス由来のペプチドを含む免疫原組成物および使用方法 |
| MX2013004149A (es) * | 2010-10-15 | 2013-09-02 | Glaxosmithkline Biolog Sa | Antigeno gb de citomegalovirus. |
| CA2823876A1 (en) * | 2011-01-07 | 2012-07-12 | Bioscience Slovakia | Viral diagnostics |
| WO2012162428A1 (en) | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
| EP3854413A1 (en) * | 2011-07-06 | 2021-07-28 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| US8834307B2 (en) | 2011-10-06 | 2014-09-16 | Kawasaki Jukogyo Kabushiki Kaisha | Belt type continuously variable transmission |
| US20140348863A1 (en) * | 2011-10-12 | 2014-11-27 | Alessia Bianchi | Cmv antigens and uses thereof |
| MX378747B (es) * | 2012-07-06 | 2025-03-10 | Glaxosmithkline Biologicals S A Star | Complejos de proteínas de citomegalovirus. |
| US9809801B2 (en) | 2013-03-15 | 2017-11-07 | Université De Genève | Anti-mycobacterial vaccines |
| AU2014359276B2 (en) | 2013-12-03 | 2021-01-28 | Hookipa Biotech Gmbh | CMV vaccines |
| PL3218504T3 (pl) | 2014-11-13 | 2021-02-08 | Université De Genève | Trójsegmentowe arenawirusy jako wektory szczepionkowe |
| WO2016198531A2 (en) | 2015-06-10 | 2016-12-15 | Hookipa Biotech Ag | Hpv vaccines |
| CN108779472B (zh) | 2015-11-04 | 2022-09-09 | 霍欧奇帕生物科技有限公司 | 针对乙型肝炎病毒的疫苗 |
| US11266727B2 (en) | 2015-11-12 | 2022-03-08 | Hookipa Biotech Gmbh | Arenavirus particles as cancer vaccines |
| MX2018013956A (es) | 2016-05-18 | 2019-07-04 | Hookipa Biotech Gmbh | Virus pichinde de tres segmentos como vectores de vacunas. |
| US20200206334A1 (en) | 2016-11-04 | 2020-07-02 | Hookipa Biotech Gmbh | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
| US20200113995A1 (en) | 2017-04-07 | 2020-04-16 | Hookipa Biotech Gmbh | Arenavirus particles to treat solid tumors |
| CN114981443A (zh) | 2019-11-07 | 2022-08-30 | 巴塞尔大学 | 作为载体的沙粒病毒 |
| IL298420A (en) | 2020-05-29 | 2023-01-01 | Hookipa Biotech Gmbh | Cancer treatment strategies using RNA virus vectors |
-
2014
- 2014-12-03 AU AU2014359276A patent/AU2014359276B2/en active Active
- 2014-12-03 PL PL14820762T patent/PL3077519T3/pl unknown
- 2014-12-03 EP EP14820762.4A patent/EP3077519B1/en active Active
- 2014-12-03 DK DK14820762.4T patent/DK3077519T3/da active
- 2014-12-03 WO PCT/EP2014/076466 patent/WO2015082570A1/en not_active Ceased
- 2014-12-03 US US15/101,363 patent/US10111945B2/en active Active
- 2014-12-03 JP JP2016536893A patent/JP6818551B2/ja active Active
- 2014-12-03 HR HRP20211015TT patent/HRP20211015T1/hr unknown
- 2014-12-03 EP EP21165671.5A patent/EP3904522A1/en not_active Withdrawn
- 2014-12-03 HU HUE14820762A patent/HUE054579T2/hu unknown
- 2014-12-03 SI SI201431830T patent/SI3077519T1/sl unknown
- 2014-12-03 CA CA2932318A patent/CA2932318C/en active Active
- 2014-12-03 RS RS20210759A patent/RS61993B1/sr unknown
- 2014-12-03 LT LTEP14820762.4T patent/LT3077519T/lt unknown
- 2014-12-03 ES ES14820762T patent/ES2868427T3/es active Active
- 2014-12-03 PT PT148207624T patent/PT3077519T/pt unknown
- 2014-12-03 CN CN201480074709.4A patent/CN105980570B/zh active Active
- 2014-12-03 CN CN202210602284.6A patent/CN115058452A/zh active Pending
-
2018
- 2018-09-20 US US16/137,323 patent/US11554169B2/en active Active
-
2020
- 2020-12-28 JP JP2020218641A patent/JP7001807B2/ja active Active
-
2021
- 2021-04-26 AU AU2021202541A patent/AU2021202541A1/en not_active Abandoned
- 2021-06-29 CY CY20211100578T patent/CY1124288T1/el unknown
-
2022
- 2022-11-22 US US18/058,116 patent/US20230181725A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PT3077519T (pt) | 2021-05-13 |
| JP6818551B2 (ja) | 2021-01-20 |
| EP3904522A1 (en) | 2021-11-03 |
| SI3077519T1 (sl) | 2021-07-30 |
| JP7001807B2 (ja) | 2022-02-04 |
| WO2015082570A1 (en) | 2015-06-11 |
| AU2021202541A1 (en) | 2021-05-27 |
| HUE054579T2 (hu) | 2021-09-28 |
| CA2932318C (en) | 2023-10-10 |
| CN105980570B (zh) | 2022-06-07 |
| JP2021061848A (ja) | 2021-04-22 |
| CN115058452A (zh) | 2022-09-16 |
| AU2014359276B2 (en) | 2021-01-28 |
| DK3077519T3 (en) | 2021-06-14 |
| US11554169B2 (en) | 2023-01-17 |
| US20190247493A1 (en) | 2019-08-15 |
| US10111945B2 (en) | 2018-10-30 |
| RS61993B1 (sr) | 2021-07-30 |
| JP2017503482A (ja) | 2017-02-02 |
| HK1226440A1 (zh) | 2017-09-29 |
| CA2932318A1 (en) | 2015-06-11 |
| CN105980570A (zh) | 2016-09-28 |
| EP3077519B1 (en) | 2021-03-31 |
| US20230181725A1 (en) | 2023-06-15 |
| LT3077519T (lt) | 2021-04-26 |
| AU2014359276A1 (en) | 2016-06-16 |
| PL3077519T3 (pl) | 2021-10-18 |
| US20160296619A1 (en) | 2016-10-13 |
| ES2868427T3 (es) | 2021-10-21 |
| HRP20211015T1 (hr) | 2021-10-01 |
| WO2015082570A8 (en) | 2015-11-26 |
| EP3077519A1 (en) | 2016-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124288T1 (el) | Cmv εμβολια | |
| MX2023013140A (es) | Vacunas contra el virus de la hepatitis b. | |
| IL262963A (en) | Tri-segmented pichinde viruses as vaccine vectors | |
| CY1123598T1 (el) | Μακροκυκλικα πεπτιδια χρησιμα ως ανοσοδιαμορφωτες | |
| CY1120893T1 (el) | Μεθοδοι για αγωγη μολυνσεων ιου filoviridae | |
| IL269391A (en) | Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy | |
| IL255106A0 (en) | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof | |
| CY1122329T1 (el) | Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων | |
| EP3480307A4 (en) | NEW GENETICALLY MODIFIED VACCINIA VIRUS | |
| MA43762A (fr) | Vaccin contre le rsv | |
| BR112017012859A2 (pt) | fosforamidatos para o tratamento do vírus da hepatite b | |
| MA46024A (fr) | Vaccin contre le virus de l'herpès simplex | |
| HUE045993T2 (hu) | Emberi immunhiány vírus antigének, vektorok, készítmények és alkalmazásukra szolgáló eljárások | |
| ZA201708039B (en) | Adenoassociated virus vectors for the treatment of mucopolysaccharidoses | |
| HUE059252T2 (hu) | Immunogén készítmények pneumokokkusz vakcinákban történõ alkalmazásra | |
| EA201790532A1 (ru) | Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса | |
| HUE063307T2 (hu) | Rák és vírusfertõzések kezelésére szolgáló immunreceptor-moduláció | |
| HUE055727T2 (hu) | Kezelt töltõanyagok, ezeket tartalmazó készítmények, és belõlük elõállított cikkek | |
| CY1120607T1 (el) | Παραγωγα ισοϊνδολινης για χρηση στη θεραπεια μιας ιικης μολυνσης | |
| EA201800148A1 (ru) | Оспенная вакцина для лечения рака | |
| IL261920A (en) | Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas | |
| IL291601A (en) | Neoglycoconjugates as vaccines and therapeutic tools | |
| CY1120573T1 (el) | Παραγωγα πυριδαζινης για χρηση στην προληψη ή θεραπεια αταξικης διαταραχης | |
| CY1122755T1 (el) | Eξισορροπημενες απο αποψη φυσιολογιας ενεσιμες μορφοποιησεις φωσνετουπιταντης | |
| EP3541419A4 (en) | IMMUNOGENIC COMPOSITION FOR MERS CORONAVIRUS INFECTION |